Johnson & Johnson (NYSE:JNJ) Shares Bought by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 0.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,616 shares of the company’s stock after buying an additional 100 shares during the quarter. EagleClaw Capital Managment LLC’s holdings in Johnson & Johnson were worth $2,744,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Hibernia Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter valued at approximately $27,000. FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $37,000. Tower View Wealth Management LLC grew its holdings in Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares during the last quarter. Creative Capital Management Investments LLC increased its position in shares of Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after purchasing an additional 86 shares during the period. Finally, VitalStone Financial LLC bought a new stake in Johnson & Johnson in the second quarter valued at $48,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $156.76 on Monday. The firm has a market capitalization of $377.37 billion, a price-to-earnings ratio of 11.35, a PEG ratio of 2.63 and a beta of 0.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The firm has a 50 day moving average price of $158.20 and a 200-day moving average price of $158.73. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The business had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the previous year, the company earned $2.35 EPS. The business’s quarterly revenue was down 9.7% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be paid a $1.19 dividend. The ex-dividend date is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Raymond James boosted their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Finally, Morgan Stanley dropped their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $176.14.

Check Out Our Latest Analysis on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.